US Patent 10,001,469: Critical claim construction and US patent landscape for in vivo GPR83 inhibitor testing and pruritus (itching) assays
US Patent 10,001,469 centers on an in vivo pruritus behavior assay that uses pharmacologic GPR83 inhibition as a readout to classify a test substance as a pruritus-related agent and as a GPR83 agonist or antagonist. The claims are method claims with explicit animal grouping, itch induction and behavioral comparison steps, and broad categories of GPR83 inhibitors (polypeptide, antibody, antisense, siRNA). The scope is anchored to GPR83 and to “itching behavior” comparisons in non-human animals, including a branching classification logic tied to suppressed or increased itching. The patent’s strength depends on how narrowly the “itching behavior” method is construed (measurand and behavioral endpoints), how courts interpret the broad inhibitor genus, and whether prior art already taught GPR83 modulation plus itch-behavior comparison using histamine/serotonin or equivalent pruritogens.
What is USPTO Patent 10,001,469 claiming, in plain infringement terms?
A process for evaluating a test substance by:
- inhibiting GPR83 in at least one animal using a defined class of GPR83 inhibitors (polypeptide, antibody, antisense, siRNA),
- administering the test substance (to one animal group or multiple groups depending on the claim),
- inducing itch using a pruritogen (in claim 3/4),
- comparing itch behavior between groups, and
- classifying the test substance based on directionality of behavioral change (suppression implies pruritus inhibition; decrease implies agonism; increase implies antagonism under claim 3’s design).
That is a tight functional algorithm built on a single biological target (GPR83) plus a single behavioral endpoint (itch).
What patents protect in vivo GPR83 inhibition testing for pruritus behavior evaluation?
USP 10,001,469 claim coverage focus
The patent is directed to method-of-testing rather than compositions for treating pruritus. This matters for freedom-to-operate (FTO): even if a third party has rights to GPR83 inhibitors or pruritogen compounds, they still face method-claim risk if they run an assay that matches the claim steps in the US.
Core claim elements mapped to likely novelty pressure points
The most litigation-relevant features are:
- Target constraint: “GPR83 inhibitor” as the enabling step.
- Inhibitor genus breadth: polypeptide, antibody, antisense inhibitor, siRNA.
- Animal comparison design: “first” and “second” non-human animals with inhibited vs not inhibited GPR83 function (claim 3) or both inhibited but different test/control substances (claim 1).
- Behavioral endpoint: “itching behavior” and comparison of increase/decrease.
- Directionality logic and classification: suppression indicates pruritus inhibition (claim 2); decrease indicates agonist, increase indicates antagonist (claim 3).
- Pruritogen limitation: histamine and serotonin (claim 4), which can be a prior-art magnet if these combinations were already used with itch models.
Adjacent patent clusters likely to overlap
Without listing hypothetical numbers, the relevant US patent landscape typically divides into four IP buckets that often collide with 10,001,469-style claims:
- GPR83 biology and modulation patents
Cover GPR83 inhibitors/antagonists/neutralizing antibodies, antisense/siRNA targeting GPR83, and compositions for inhibiting or blocking GPR83 signaling.
- Pruritus models and itch-behavior assay patents
Cover animal itch induction, behavioral scoring methods, and classification logic for pruritogen-induced scratching/itching.
- Method-of-identifying pruritus-related compounds
Cover screening and testing methods that use behavioral endpoints and directionality logic.
- Agonist vs antagonist classification assays for GPCR targets
Cover comparator designs in vivo where one group has target modulation and another does not, with pruritogen challenge.
US Patent 10,001,469 sits at the intersection of those buckets.
How strong are the claims of US Patent 10,001,469 against prior art for itch assays?
Where the claim is likely strongest
- Targeted inhibition plus itch endpoint: Many itch assays are general; this claim requires GPR83 inhibition as a prerequisite to testing.
- Two-group comparator architecture (claim 3): Using one group with inhibited GPR83 and one group with intact GPR83 function, followed by itch induction and directionality classification, is a specific experimental logic.
- Explicit classification by agonist/antagonist using directionality: The claim does not just say “compare itch.” It ties outcomes to agonist/antagonist status of the test substance relative to GPR83 under the assay’s design.
Where the claim is likely most vulnerable
- Broad inhibitor genus (polypeptide/antibody/antisense/siRNA): If prior art already disclosed GPR83 inhibition by any of these modalities in animal pruritus models, the novelty of “using a GPR83 inhibitor of these types” can be undercut.
- Behavioral endpoint generality (“itching behavior”): If the patent does not tightly define how itching is measured (frequency, duration, scoring rubric), prior art itch-model methods may be found to read on “itching behavior” even if details differ.
- Pruritogen limitation in claim 4: Histamine and serotonin are common itch inducers in rodent models. If prior patents already used histamine or serotonin to induce itching in vivo while comparing treated vs control animals, claim 4 can be vulnerable as an expected variant.
- Directionality mapping (agonist vs antagonist): Courts and examiners scrutinize whether prior art taught the same directionality inference from the same comparator design. If earlier art used the same logic but with different classification labels, the mapping can still be argued to anticipate or render obvious.
Critical construction issues likely to drive validity and infringement
- Does “in vivo” plus “non-human animal” include any species and any route?
The claim does not constrain species or route. That broadens both infringement and invalidity surfaces.
- How is “administering a GPR83 inhibitor” interpreted?
If a competitor uses a GPR83 antagonist small molecule instead of a polypeptide/antibody/antisense/siRNA, literal infringement may be avoided for claims that require selection from the listed group. This is a key design-around lever.
- What qualifies as “increasing or decreasing itching behavior”?
If the patent does not specify thresholds, prior art could satisfy “increase/decrease” qualitatively.
What is the claim scope for classifying a test substance as a pruritus inhibiting agent vs GPR83 agonist/antagonist?
Claim 1: pruritus-related substance classification
Claim 1 is oriented to whether the test substance is a “pruritus-related substance based on an increase or decrease in itching behavior.” The structure is:
- inhibit GPR83 in both a first and a second non-human animal (via one inhibitor),
- administer the test substance to the first animal,
- administer a control substance to the second,
- compare itching behavior,
- classify based on directionality.
Practical interpretation: It covers assays where both groups have GPR83 inhibited, and the test substance is the variable.
Claim 2: pruritus inhibiting determination
Claim 2 narrows claim 1 with a specific rule: suppressed itching in the first animal means the first test substance is a pruritus inhibiting substance.
Critical difference: Claim 2 eliminates ambiguity by setting the decision boundary as “suppressed.”
Claim 3: agonist vs antagonist classification with a non-inhibited comparator
Claim 3 is broader in the number of groups or dosing conditions implied by:
- administer a GPR83 inhibitor to a first non-human animal,
- administer the test substance to the first animal,
- administer the test substance to a second animal in which GPR83 function is not inhibited,
- administer a compound that induces itching to both animals,
- compare itching behavior,
- map directionality to agonist/antagonist:
- decrease in itching in the inhibited group vs non-inhibited group indicates “agonist of GPR83,”
- increase indicates “antagonist of GPR83.”
Key practical effect: Claim 3 requires a “with vs without GPR83 inhibition” comparator under itch induction.
Claim 4: histamine/serotonin limitation
Claim 4 adds: the itching-inducing compound is histamine and serotonin.
Design impact: Restricting to these pruritogens can limit infringement if a competitor uses different pruritogens (eg, IL-31, chloroquine, substance P, PAR agonists) or uses combination schemes.
When does US Patent 10,001,469 lose exclusivity, and what term drivers matter?
The exclusivity/term for a US utility patent depends on filing date and prosecution history (and potentially patent adjustment). This analysis cannot be completed from the information provided because it requires:
- the application filing date and status,
- whether it is subject to terminal disclaimer,
- PTA (patent term adjustment),
- any B-delay, and
- whether the patent issued from a continuation that changed term calculations.
Given the constraint to provide a complete and accurate response, the exclusivity timeline cannot be stated here.
What Orange Book status applies to US Patent 10,001,469?
US Patent 10,001,469 is a utility patent directed to an in vivo evaluation method. Method patents generally do not populate the FDA Orange Book, which is organized around approved drug products and listed drug-substance and drug-product patents tied to marketing exclusivity.
A definitive Orange Book status cannot be produced from the claim text alone.
How do Paragraph IV and biosimilar challenges relate to US Patent 10,001,469?
Paragraph IV certifications apply to ANDA-related Orange Book-listed patents for small molecules. Biosimilar exclusivity relates to BLAs and reference product exclusivity.
For 10,001,469, a direct pathway mapping to Paragraph IV or biosimilar litigation depends on whether it is listed in the Orange Book for a specific NDA/ANDA product. That listing status is not determinable from the claim excerpt alone.
What claim workarounds exist: where can competitors design around the patent?
Under the claim language provided, the most direct design-around opportunities are structural:
-
Use a GPR83 inhibitor modality not covered by the claim’s enumerated genus
Claims 1 and 3 require the GPR83 inhibitor to be selected from: polypeptide, antibody, antisense inhibitor, siRNA. If a competitor uses a different inhibitor class not meeting that selection, literal infringement may be avoided.
This is the most meaningful scoping lever because it attacks the “selected from the group” limitation.
-
Avoid the exact comparator architecture
- Claim 1 requires both a first and second animal with GPR83 inhibited and different administered substances (test vs control).
- Claim 3 requires a first inhibited animal and a second animal where GPR83 function is not inhibited, plus itch induction in both.
A competitor can potentially avoid by altering the study design such that the “not inhibited” condition (or the test/control distribution) is not met.
-
Avoid histamine/serotonin in the itch-inducing step
Claim 4 is limited to histamine and serotonin. If a competitor uses other pruritogens (or does not use both histamine and serotonin as specified), claim 4 is harder to capture. Claim 3 would still be in play if the pruritogen limitation is not required there.
-
Change the endpoint inference
Claim 2 and claim 3 contain explicit classification rules from directionality. If a competitor does not use those decision rules, literal infringement may be avoided depending on how courts treat the “wherein … indicates” language and whether the method is practiced “comprising” those steps.
Which technical and regulatory practices most likely increase infringement risk for method-of-testing claims?
Risk concentrates on assay replication by:
- preclinical pharmacology teams running in vivo pruritus models,
- translational teams screening candidate pruritogen modulators,
- CROs offering “in vivo GPCR itch assay” services for GPR83-targeted candidates.
The most relevant operational factors (for infringement) are:
- whether the study uses a listed-form GPR83 inhibitor modality (polypeptide/antibody/antisense/siRNA),
- whether it uses a two-group comparator with inhibited vs not inhibited GPR83 function (claim 3),
- whether itch is induced with histamine and serotonin in the formulation used for claim 4,
- whether outcomes are used to make the specific “pruritus inhibiting” or “agonist vs antagonist” determinations as written.
How does US Patent 10,001,469 compare with common GPR83-IP patterns in US practice?
What is unusual
Method patents with explicit GPCR inhibition and itch-behavior directionality can be narrower than broad “use for treating pruritus” claims, but they can also be potent in litigation if a defendant runs the same screening protocol during development.
What is common
- Target-specific assay framing (GPR83 as the enabling biological axis).
- Use of itch-inducing compounds like histamine/serotonin for animal itch models.
- Comparator animal design to distinguish on-target modulation effects.
Where overlap is likely
If there are earlier GPR83 biology patents that include animal itch assays with GPR83 modulation, those can raise validity pressure for 10,001,469 depending on whether they already disclose the same classification logic and comparator framework.
Key Takeaways
- US Patent 10,001,469 is a target-specific in vivo assay patent for evaluating whether a test substance modulates pruritus via GPR83, using itch-behavior directionality.
- Claim 1 covers evaluating a test substance under GPR83 inhibition with a test-vs-control comparator.
- Claim 3 adds a non-inhibited comparator group and ties directionality differences to agonist vs antagonist classification relative to GPR83.
- Claim 4 narrows the itch-inducing compound to histamine and serotonin.
- The highest-value design-around surfaces in the provided language are: (i) using a GPR83 inhibitor modality outside the enumerated genus, (ii) changing the comparator architecture around inhibited vs not inhibited GPR83 function, and (iii) avoiding histamine/serotonin for the claim 4 itch induction step.
- Exclusivity, Orange Book status, and Paragraph IV/biosimilar relevance cannot be stated from the claim excerpt alone.
FAQs
1) Does using a small-molecule GPR83 inhibitor infringe if claims list only polypeptide/antibody/antisense/siRNA?
Claim infringement depends on whether the accused inhibitor fits the “selected from the group consisting of” limitation as construed by the court.
2) If a study measures itching by scratching frequency, does it meet “itching behavior”?
Literal coverage turns on claim construction of “itching behavior” and whether the measured behavior is the same behavioral phenomenon the claim contemplates.
3) Can a company avoid claim 3 by using only inhibited animals and no “not inhibited” comparator?
Claim 3’s language requires a second non-inhibited condition, so eliminating that comparator can reduce literal infringement risk.
4) Is claim 4 limited to using both histamine and serotonin, or either one?
The claim text states the itching-inducing compound is selected from histamine and serotonin; the scope depends on “selected from” interpretation and the exact pruritogen regimen used.
5) What type of US litigation posture typically targets method-of-testing patents like this?
Enforcement typically occurs via development-stage activity: preclinical screening protocol replication by infringers or CROs performing the covered method for defendants’ programs.
References (APA)
- United States Patent 10,001,469 (claims excerpt provided by user).
